Systemic Therapy for Rosacea.

Oral antibiotics have been used off-label for the aid of rosacea since the 1950s because it was believed that microorganisms were causative. We now know that there is little to no grounds supporting this premise. Although not curative, the observed benefits of oral antibiotic communicating in patients with rosacea have made clinicians and patients reluctant to exclude these agents from their therapeutic armamentarium, much less to downgrade them from their first-line position.


Due to the chronicity of this disease, antibiotic use is often long-term and can produce side-effects. Furthermore, overuse of antibiotics is associated with the emersion of resistant strains of bacteria that have the potential drop to solvent in adverse global well-being consequences.
Tetracycline received US FDA message in 1952 and the derivatives doxycycline and minocycline soon followed in 1966 and 1972, respectively. At the time of their movement, they were known to be bacteriostatic and have broad-spectrum legal proceeding. Since then, we have come to recognize the anti-inflammatory properties of the tetracycline educational activity of antibiotics.